Diagnostic Criteria for Hepatorenal Syndrome

Current Diagnostic Criteria for HRS-AKI

• The International Club of Ascites recommends diagnosis of cirrhosis and ascites for hepatorenal syndrome diagnosis 1, 2
• The International Club of Ascites-Acute Kidney Injury criteria should be used to diagnose AKI in hepatorenal syndrome diagnosis 1, 3
• No response after 2 consecutive days of diuretic withdrawal and plasma volume expansion with albumin 1 g/kg body weight is required for hepatorenal syndrome diagnosis 3, 2
• Absence of shock is necessary for hepatorenal syndrome diagnosis 1, 3
• No current or recent use of nephrotoxic drugs, such as NSAIDs, aminoglycosides, and iodinated contrast media, is required for hepatorenal syndrome diagnosis 1, 2
• The absence of proteinuria (>500 mg/day) and microhematuria (>50 red blood cells per high power field) indicates no signs of structural kidney injury in hepatorenal syndrome diagnosis 3, 2
• Normal findings on renal ultrasonography indicate no signs of structural kidney injury in hepatorenal syndrome diagnosis 1, 3

AKI Staging in HRS Diagnosis

• The American Association for the Study of Liver Diseases recommends AKI staging according to the following criteria: Stage 1, increase of creatinine ≥0.3 mg/dL up to 2-fold of baseline; Stage 2, increase in creatinine between 2-fold and 3-fold of baseline; Stage 3, increase in creatinine >3-fold of baseline or creatinine >4 mg/dL with an acute increase ≥0.3 mg/dL or initiation of renal replacement therapy 1, 4

Evolution of HRS Diagnostic Criteria

• The European Association for the Study of the Liver previously required a doubling of serum creatinine to a value >2.5 mg/dL within 2 weeks for type 1 HRS diagnosis, but this criterion has been removed in updated guidelines 3, 5
• Earlier treatment leads to better outcomes in hepatorenal syndrome, according to the European Association for the Study of the Liver 5

Differential Diagnosis Considerations

• HRS accounts for 15-43% of AKI cases in cirrhotic patients, while other common causes include hypovolemia (27-50% of cases) and acute tubular necrosis (14-35% of cases), according to the American Association for the Study of Liver Diseases 1, 4
• Biomarkers such as urinary neutrophil gelatinase-associated lipocalin (NGAL) and other biomarkers (KIM-1, IL-18, L-FABP) may help differentiate HRS from acute tubular necrosis, as suggested by the European Association for the Study of the Liver 3, 5

Clinical Implications

• Early diagnosis is critical as HRS carries high mortality (median survival of untreated type 1 HRS is approximately 1 month), according to the European Association for the Study of the Liver 6
• The American Association for the Study of Liver Diseases recommends treatment with vasoconstrictors (terlipressin) plus albumin for hepatorenal syndrome 7, 6
• Liver transplantation remains the definitive treatment for HRS, according to the European Association for the Study of the Liver 7
• Prevention strategies include albumin infusion with antibiotics when treating spontaneous bacterial peritonitis, as recommended by the American Association for the Study of Liver Diseases 1, 7

Hepatorenal Syndrome: Pathophysiology and Clinical Implications

Pathophysiology

• Arterial underfilling triggers activation of the sympathetic nervous system and renin-angiotensin-aldosterone system (RAAS), causing renal vasoconstriction, according to the European Association for the Study of the Liver 8
• Impaired cardiac function due to cirrhotic cardiomyopathy leads to inadequate cardiac output to compensate for vasodilation, as reported by the European Association for the Study of the Liver 8
• Increased synthesis of vasoactive mediators affects renal blood flow and glomerular microcirculation, as noted by the European Association for the Study of the Liver 8

Classification

• Type 1 HRS (now termed HRS-AKI) is characterized by rapid, progressive renal impairment with serum creatinine increasing ≥100% to >2.5 mg/dl in less than 2 weeks, as defined by the European Association for the Study of the Liver 8
• Type 2 HRS (now termed HRS-CKD) features stable or less progressive impairment in renal function with a more chronic course, according to the European Association for the Study of the Liver 8

Diagnostic Criteria

• No improvement of serum creatinine after 2 consecutive days of diuretic withdrawal and plasma volume expansion with albumin (1 g/kg body weight, maximum 100 g/day) is a diagnostic criterion for HRS, as specified by the European Association for the Study of the Liver 8
• Absence of parenchymal renal disease as indicated by no proteinuria (>500 mg/day) is a diagnostic criterion for HRS, according to the European Association for the Study of the Liver 8
• Absence of parenchymal renal disease as indicated by no microhematuria (>50 red blood cells per high power field) is a diagnostic criterion for HRS, as reported by the European Association for the Study of the Liver 8
• Normal findings on renal ultrasonography is a diagnostic criterion for HRS, as noted by the European Association for the Study of the Liver 8

Risk Factors and Prognosis

• Bacterial infections, particularly spontaneous bacterial peritonitis (SBP), are the most important risk factors for HRS development, according to the European Association for the Study of the Liver 8
• HRS develops in approximately 30% of patients with SBP, as reported by the European Association for the Study of the Liver 8
• Prognosis is poor, with median survival of untreated type 1 HRS approximately 1 month, as noted by the European Association for the Study of the Liver 8
• High MELD scores and type 1 HRS are associated with very poor prognosis, according to the European Association for the Study of the Liver 8

Prevention Strategies

• Albumin infusion with antibiotics when treating spontaneous bacterial peritonitis may help prevent HRS, as suggested by the European Association for the Study of the Liver 8

Diagnostic Criteria for Hepatorenal Syndrome

Core Diagnostic Requirements

• The International Club of Ascites consensus criteria require ALL of the following for diagnosing Hepatorenal Syndrome (HRS) in patients with cirrhosis and ascites: cirrhosis with ascites, AKI defined by ICA-AKI criteria, no improvement in serum creatinine after 2 consecutive days of diuretic withdrawal and plasma volume expansion with albumin, absence of shock, no current or recent nephrotoxic drug use, and no evidence of structural kidney injury 9, 10

Critical Evolution from Old Criteria

• The fixed threshold of serum creatinine >1.5 mg/dL has been abandoned because it often signifies severely reduced GFR and delays diagnosis, and the newer criteria emphasize dynamic changes in creatinine rather than absolute values, allowing earlier detection and treatment 9, 10
• Earlier treatment leads to better outcomes, and median survival of untreated type 1 HRS is only approximately 1 month 11

Common Pitfalls to Avoid

• Do not wait for creatinine to reach 1.5 mg/dL before considering HRS—use the dynamic AKI criteria instead, and do not rely on urine output as a diagnostic criterion in cirrhotic patients with ascites 9, 10
• Consider renal biopsy if proteinuria, microhematuria, or abnormal kidney size is present to evaluate for parenchymal disease and guide combined liver-kidney transplant decisions 11

Clinical Context

• Bacterial infections, particularly spontaneous bacterial peritonitis (SBP), are the most important risk factor—HRS develops in approximately 30% of patients with SBP, and high MELD scores and type 1 HRS carry very poor prognosis with median survival of approximately 3 months overall and 1 month for untreated type 1 HRS 11

Hepatorenal Syndrome Pathophysiology and Precipitants

Primary Underlying Mechanism

• The American Association for the Study of Liver Diseases suggests that cirrhosis with portal hypertension creates a cascade of hemodynamic disturbances, including splanchnic arterial vasodilation, increased sinusoidal hydrostatic pressure, and effective arterial underfilling, leading to intense renal vasoconstriction in patients with hepatorenal syndrome 12, 13
• Effective arterial underfilling triggers activation of the sympathetic nervous system and renin-angiotensin-aldosterone system (RAAS), leading to intense renal vasoconstriction in patients with cirrhosis and portal hypertension 12, 13

Major Precipitating Factors

• Bacterial infections, such as spontaneous bacterial peritonitis, can precipitate hepatorenal syndrome by inducing further splanchnic vasodilation and worsening circulatory dysfunction in patients with cirrhosis 13
• Volume depletion due to aggressive diuretic use, large-volume paracentesis without albumin replacement, or gastrointestinal bleeding can also precipitate hepatorenal syndrome in patients with cirrhosis 12, 13
• Any acute deterioration in liver function can contribute to the development of hepatorenal syndrome in patients with cirrhosis 12

Advanced Pathophysiological Contributors

• Increased gut permeability from portal hypertension allows bacterial translocation, contributing to systemic inflammation and hepatorenal syndrome in patients with cirrhosis 12

Important Clinical Context

• Severe or repeated episodes of renal hypoperfusion can lead to structural kidney damage over time, exposing patients to direct hemodynamic injury and challenging the traditional view of hepatorenal syndrome as purely reversible 12

Cardiovascular Contributions to Hepatorenal Syndrome

Impaired Cardiac Contractility in Cirrhosis

• Cirrhotic cardiomyopathy reduces the heart’s contractile ability, limiting the capacity to increase cardiac output in response to systemic vasodilation and thereby aggravating renal hypoperfusion. 14

Reduced Cardiac Output as a Manifestation of Cirrhotic Cardiomyopathy

• In patients with advanced cirrhosis and ascites, a lowered cardiac output is a typical expression of cirrhotic cardiomyopathy, contributing to the development of hepatorenal syndrome. 14

Diastolic Dysfunction as a Prognostic Indicator

• The severity of diastolic dysfunction correlates with survival: patients without diastolic dysfunction have approximately 95 % survival, those with mild (grade I) dysfunction about 79 %, and those with moderate (grade II) dysfunction about 39 % survival. 14

Reduced Cardiac Output Increases Risk of Acute Kidney Injury After Infection

• A diminished cardiac output predisposes cirrhotic patients to acute kidney injury—including hepatorenal syndrome—following bacterial infections such as spontaneous bacterial peritonitis. 14

Key Evidence‑Based Findings on Hepatorenal Syndrome Pathophysiology and Diagnosis

Hemodynamic Mechanisms

• Portal hypertension induces splanchnic arterial vasodilation, creating a hyperdynamic circulatory state with reduced effective arterial blood volume and lower mean arterial pressure. 15
• The resulting arterial under‑filling activates the sympathetic nervous system and the renin‑angiotensin‑aldosterone system, leading to intense renal vasoconstriction and a right‑ward shift of the renal autoregulatory curve. 15
• Cirrhotic cardiomyopathy diminishes cardiac contractility, limiting the ability of cardiac output to compensate for systemic vasodilation and thereby aggravating renal hypoperfusion. 15

Inflammatory and Molecular Mechanisms

• Modern evidence recognizes systemic inflammation as a direct contributor to hepatorenal syndrome, beyond pure hemodynamic disturbance. 15
• Pro‑inflammatory cytokines and chemokines act on proximal tubular epithelial cells, causing mitochondria‑mediated metabolic down‑regulation and reduced sodium‑chloride reabsorption. 15
• The resulting increase in sodium‑chloride delivery to the macula densa stimulates intrarenal RAAS activation, further decreasing glomerular filtration rate. 15
• Severe cholestasis can exacerbate renal dysfunction by intensifying systemic inflammation and macrocirculatory impairment. 15

Diagnostic Considerations

• A baseline electrocardiogram should be obtained before initiating vasoconstrictor therapy for hepatorenal syndrome to identify potential cardiac contraindications. 15